Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
651.38B
Market cap651.38B
Price-Earnings ratio
30.99
Price-Earnings ratio30.99
Dividend yield
1.96%
Dividend yield1.96%
Average volume
6.32M
Average volume6.32M
High today
$272.66
High today$272.66
Low today
$267.00
Low today$267.00
Open price
$268.10
Open price$268.10
Volume
6.19M
Volume6.19M
52 Week high
$276.47
52 Week high$276.47
52 Week low
$173.33
52 Week low$173.33

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $271.00, with a market capitalization of 651.38B. The stock trades at a price-to-earnings (P/E) ratio of 30.99 and offers a dividend yield of 1.96%.

On 2026-08-21, Johnson & Johnson(JNJ) stock moved within a range of $267.00 to $272.66. With shares now at $271.00, the stock is trading +1.5% above its intraday low and -0.6% below the session's peak.

Trading volume for Johnson & Johnson(JNJ) stock has reached 6.19M, versus its average volume of 6.32M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $276.47 and a low of $173.33.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $276.47 and a low of $173.33.

JNJ News

The Motley Fool 6h
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?

The iShares U.S. Pharmaceuticals ETF (IHE +1.01%) offers a lower-cost entry into diversified pharmaceutical leaders, while the Invesco Biotechnology & Genome ET...

Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?
Reuters 7h
Johnson & Johnson names new vice president for litigation - Reuters

...

Johnson & Johnson names new vice president for litigation - Reuters
Nasdaq 15h
Merck vs. J&J: Which Healthcare Giant Should Investors Choose?

Johnson & Johnson JNJ and Merck MRK are two of the largest U.S. healthcare companies, making them compelling stocks to compare. Both companies have strong posi...

Merck vs. J&J: Which Healthcare Giant Should Investors Choose?

Analyst ratings

73%

of 26 ratings
Buy
73.1%
Hold
23.1%
Sell
3.8%

More JNJ News

Simply Wall St 1d
How Investors May Respond To Madrigal Adding J&J R&D Leader John C. Reed To Its Board

On August 12, 2026, Madrigal Pharmaceuticals announced it had appointed John C. Reed, M.D., Ph.D., Johnson & Johnson’s Executive Vice President of Innovative Me...

How Investors May Respond To Madrigal Adding J&J R&D Leader John C. Reed To Its Board
24/7 Wall St. 2d
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO By Trey Thoelcke Published Aug 20, 10:40AM EDT Quick Read SPTX's Glyph prodrug pl...

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
TipRanks 2d
Analysts Back Dividend Aristocrats JNJ and LIN Ahead of Q3 Earnings

Johnson & Johnson (JNJ) and Linde (LIN) are two of the dividend aristocrat stocks rated Strong Buy by analysts covering the stocks, according to TipRanks’ Divid...

24/7 Wall St. 3d
How Much Do You Need Invested at 55 to Bridge the Gap Until Social Security at 62?

How Much Do You Need Invested at 55 to Bridge the Gap Until Social Security at 62? By Michael Williams Published Aug 19, 5:24AM EDT Quick Read Generating $60,...

How Much Do You Need Invested at 55 to Bridge the Gap Until Social Security at 62?
TipRanks 3d
JNJ-Backed Lung Biopsy Scanner Study Signals New Edge in Cancer Diagnostics

Johnson & Johnson (JNJ) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confid...

Nasdaq 4d
November 20th Options Now Available For Johnson & Johnson

Investors in Johnson & Johnson (Symbol: JNJ) saw new options become available today, for the November 20th expiration. One of the key data points that goes into...

November 20th Options Now Available For Johnson & Johnson
Nasdaq 4d
J&J's New Growth Powerhouses: Immunology and Neuroscience

Johnson & Johnson JNJ is a leading player in oncology, with the segment accounting for around 29% of total company revenues and approximately 45% of Innovative...

J&J's New Growth Powerhouses: Immunology and Neuroscience

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.